Condition
Solid Tumor in Advanced Stage
Total Trials
3
Recruiting
1
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
P 1 (3)
Trial Status
Completed2
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT06911333Phase 1Recruiting
AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors
NCT01305512Phase 1CompletedPrimary
Pharmacokinetic, Safety and Tolerability Study of SPARC1028
NCT01304303Phase 1CompletedPrimary
Pharmacokinetic and Safety Study of SPARC1023 Alone and in Carboplatin Combination
Showing all 3 trials